Claims for Patent: 6,737,427

Summary for Patent: 6,737,427

Title:	Mucin synthesis inhibitors
Abstract:	The claimed invention relates to methods of modulating mucin synthesis and the therapeutic application of compounds in controlling mucin over-production associated with diseases such as chronic obstructive pulmonary diseases (COPD) including asthma and chronic bronchitis, inflammatory lung diseases, cystic fibrosis and acute or chronic respiratory infectious diseases.
Inventor(s):	Zhou; Yuhong (Dreshler, PA), Levitt; Roy C. (Ambler, PA), Nicolaides; Nicholas C. (Media, PA), Jones; Steve (West Chester, PA), McLane; Mike (Lansdale, PA)
Assignee:	Genaera Corporation (Plymouth Meeting, PA)
Application Number:	09/774,243
Patent Claims:	1. A method of treating a subject with a disease characterized by the production of mucin, comprising administering to the subject an effective amount of a composition comprising a 2-aminophenyl acetic acid compound or a pharmaceutically acceptable salt thereof. 2. A method of claim 1, wherein the disease is selected from the group consisting of a chronic obstructive pulmonary disease (COPD), an inflammatory lung disease, and an acute or chronic infectious disease. 3. A method of claim 1, wherein the mucin production occurs in the respiratory tract of the subject. 4. A method of claim 1, wherein the mucin production occurs in the gastrointestinal tract of the subject. 5. A method of claim 4, wherein the mucin production occurs in the pancreas of the subject. 6. A method of claim 2, wherein the disease is asthma. 7. A method of claim 2, wherein the disease is bronchitis. 8. A method of claim 2, wherein the disease is chronic bronchitis. 9. A method of claim 2, wherein the disease is cystic fibrosis. 10. A method of claim 2, wherein the disease is emphysema. 11. A method of claim 2, wherein the disease is gastrointestinal malabsorption syndrome. 12. A method of claim 2, wherein the disease is steatorrhea. 13. A method of claim 2, wherein the disease is diarrhea. 14. A method of claim 2, wherein the disease is allergic inflammation. 15. A method of claim 2, wherein the treatment reduces airway inflammation. 16. A method of claim 2, wherein the treatment reduces inflammatory cells. 17. A method of claim 2, wherein the treatment reduces epithelial-related inflammation. 18. A method of claim 1, wherein the treatment is for bronchial hyperresponsiveness. 19. A method of claim 1, wherein the treatment down-regulates mediators of airway inflammation. 20. A method of claim 19, wherein the mediator is a chemokine. 21. A method of claim 19, wherein the mediator is a cytokine. 22. A method of claim 20, wherein the cytokine is interleukin 9. 23. A method of claim 1, wherein the treatment decreases the number of goblet cells in the respiratory tract. 24. A method of claim 1, wherein the treatment decreases the number of goblet cells in the gastrointestinal tract. 25. A method of claim 1, wherein the treatment decreases the number of submucosal glands in the respiratory tract. 26. A method of claim 1, wherein the treatment decreases the number of submucosal glands in the gastrointestinal tract. 27. A method of claim 1, wherein the 2-amino phenylacetic acid compound is talniflumate or a pharmaceutically acceptable salt thereof. 28. A method of claim 27, wherein the composition consists essentially of talniflumate. 29. A method of claim 1, wherein the 2-aminophenyl acetic acid compound is formulated as a prodrug. 30. A method of claim 1, wherein the 2-aminophenyl acetic acid compound inhibits chloride channel activity. 31. A method of claim 30, wherein the chloride channel is a calcium activated chloride channel. 32. A method of claim 31, wherein the calcium activated chloride channel is human CLCA1 or CLCA2. 33. A method of claim 30, wherein the 2-aminophenyl acetic acid compound is talniflumate. 34. A method of claim 1, wherein the composition is administered by a systemic route. 35. A method of claim 34, wherein the composition is administered by a parenteral route. 36. A method of claim 35, wherein the parenteral route is selected from the group consisting of intravenous, intramuscular, intraperitoneal and subcutaneous administration. 37. A method of claim 15, wherein the composition is formulated as a suppository for subcutaneous or intramuscular injection. 38. A method of claim 1, wherein the composition is administered by an oral route. 39. A method of claim 38, wherein the composition is formulated for oral administration in a formulation selected from the group consisting of capsules, tablets, elixirs, suspensions and syrups. 40. A method of claim 38, wherein the composition is formulated as a controlled release formulation. 41. A method of claim 1, wherein the composition further comprises a pharmaceutically acceptable carrier. 42. A method of claim 41, wherein the pharmaceutically acceptable carrier is selected from the group consisting of a surfactant, stabilizing agent, encapsulating agents, and absorption-enhancing agent. 43. A method of claim 41, wherein the pharmaceutically acceptable carrier is sterile water or sterile oil. 44. A method of claim 42, wherein the sterile oil is selected from the group consisting of petroleum, animal, vegetable, peanut, soybean, mineral and sesame oil. 45. A method of claim 41, wherein the pharmaceutically acceptable carrier is selected from the group consisting of saline, glycerol and dextrose solutions. 46. A method of claim 1, wherein the composition is administered by inhalation. 47. A method of claim 46, wherein the composition is in the form of an aerosol. 48. A method of claim 1, wherein the composition is administered by an inhaler. 49. A method of claim 48, wherein the inhaler is a metered dose inhaler. 50. A method of claim 48, wherein the inhaler is a dry powder inhaler. 51. A method of claim 1, wherein the composition is administered in a topical formation as a solution, suspension, gel, ointment or salve. 52. A method of claim 1, wherein the composition is administered in combination with a second agent for the treatment of any of the diseases listed in claims 6 to 14. 53. A method of claim 52, wherein the second agent is selected from the group consisting of expectorants, mucolytics, antibiotics, antihistamines, steroids, anti-inflammatory agents, and decongestants. 54. A method of claim 52, wherein the second agent is a beta receptor agonist. 55. A method of claim 52, wherein the second agent is a steroid. 56. A method of claim 52, wherein the second agent is a leukotriene antagonist. 57. A method of treating a subject with a disease characterized by the production of mucin, comprising administering to the subject an effective amount of a composition comprising talniflumate or a pharmaceutically acceptable salt thereof. 58. A method of treating cystic fibrosis in a subject in need of such treatment comprising administering to the subject an effective amount of a composition comprising talniflumate or a pharmaceutically acceptable salt thereof. 59. A method of treating cystic fibrosis in a subject in need of such treatment comprising administering to the subject an effective amount of a composition consisting essentially of talniflumate or a pharmaceutically acceptable salt thereof.

Details for Patent 6,737,427

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2016-08-23
Aimmune Therapeutics, Inc.	PALFORZIA	peanut (arachis hypogaea) allergen powder	Powder	125696	01/31/2020		2016-08-23